Developing an effective glycoconjugate vaccine against Group A Streptococcus causing rheumatic fever/heart disease

在全球范围内，澳大利亚原住民和托雷斯海峡岛民的A组链球菌（GAS）感染率最高，主要是风湿性心脏病和风湿热。GAS感染是一种地方性疾病，由于感染后的问题，通常是致命的。本项目旨在开发一种糖缀合物疫苗来预防GAS感染。我们的目标是通过从GAS蛋白的小的特定部分制备疫苗，使身体产生安全的抗体来阻止GAS及其相关疾病，从而避免这些死亡。

Globally Australian Aboriginal and Torres Strait Islanders have the highest recorded rate of Group A Streptococcus (GAS) infection, mainly rheumatic heart disease and rheumatic fever. GAS infection is endemic and often fatal due to post-infection problems.This project aims to develop a glycoconjugate vaccine to prevent GAS infection.We aim to avert these deaths by making a vaccine from small, specific parts of GAS proteins so the body makes safe antibodies that stop GAS and its related diseases.